Feb 15, 2019

Bioinfogate will be showcasing some of their recent developments at the Society of Toxicology’s 58th Annual Meeting and ToxExpo in Baltimore, MD, March 10-14 2019.

At the exhibition (booth 4210), the latest version of our translational safety intelligence portal OFF-X will be presented, including new and forthcoming enhancements like the expansion of the Drugs&Biologics area or the launch of the Additional References section, developed in order to expand the coverage of targets in the system.

A series of case studies will be presented to demonstrate OFF-X’s utility for a wide variety of professionals including:

  • Biologists and Bioinformaticians, to perform new target safety assessment
  • Medicinal Chemists, to identify potential toxicophores and optimize hit compounds
  • Data Scientists, to build predictive and AI models using OFF-X’s high quality curated and structured dataset
  • Toxicologists and Non-Clinical Safety Researchers, to analyze data for regulatory endpoints of interest, assess secondary pharmacology and potential off-target liabilities
  • Clinical Researchers, to optimize clinical trial design, understand mechanistic toxicity of adverse events observed in clinical trials and to benchmark competitors’ safety profiles
  • Pharmacovigilance teams to discover unknown adverse events and support understanding of safety alerts
  • Regulatory professionals, to facilitate mandatory reporting requirements of regulatory bodies
  • Business Development Analysts, to enhance due diligence of potential in-licensing opportunities

Since its launch in 2017, Bioinfogate OFF-X has been providing integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of R&D, including first-in-class and emerging targets. OFF-X allows prompt identification of toxicology and safety signals and de-risking of R&D projects. As of February 2019, the portal covers a range of 7,000 targets and 9,000 drugs & biologics, and is populated with more than 260,000 expertly curated safety alerts and 500,000 references of interest associated to 4,000 adverse effects. OFF-X is used across pharma and biotech organizations, in leading research centers and regulatory bodies (for more information visit

For further information or to schedule a meeting during the conference, please contact


About Society of Toxicology (SOT)

SOT, founded in 1961, is a professional and scholarly organization of scientists from academic institutions, government, and industry representing scientists who practice toxicology in the US and abroad. The Society’s mission is to create a safer and healthier world by advancing the science and increasing the impact of toxicology. The SOT Annual Meeting hosts 6,000+ participants from the fields of toxicology, safety, regulation, risk assessment and more.


About Bioinfogate

Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry-leading solutions and identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.

Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007; acquired by Thomson Reuters in 2007), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.


Sep 17, 2018

Bioinfogate has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting “Drug Lifecycle Management and Regulatory Sciences – Frontier of AI-driven Drug Discovery Age” which takes place in Tokyo, Oct. 9-11, 2018.

During the Focused Session FS08 “Computational toxicology – practical and application”,  (Tue Oct. 9, 16:00-17:30), Josep Prous, Jr., Ph.D., Executive Director at Bioinfogate, will present “Interactomics technologies in the discovery of emerging drug target safety issues”.

The interactome can be defined as the global biologically relevant interactions that form a highly connected network. It can be understood as a map to investigate how individual genetic perturbations (i.e. the target modulation effect of a drug) propagate through the network and impact the system as a whole.

In his presentation, Dr Prous, Jr. will introduce how the the OFF-X translational safety portal coupled to advanced methods in protein -protein interaction networks can lead to:

  • Identification of potential safety liabilities associated to new targets by analyzing the neighborhood of our target of interest,
  • Assessment of adverse events safety hotspots
  • Better understanding of mechanisms of toxicity

The OFF-X Safety Maps initiative is the first interactome-based solution which considers target safety information from early discovery to pharmacovigilance, providing a unique collection of adverse event – target/action associations.


For further information or to schedule a meeting during the conference, please contact


About the Chem-Bio Informatics Society

The Chem-Bio Informatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society is interested in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.


About Bioinfogate

Bioinfogate, a leading data science organization, is the producer of the OFF-X portal ( OFF-X is the first translational safety intelligence portal that allows drug R&D scientists to be promptly informed about the target modulating effects of small molecules and biologics leading to preclinical toxicity and clinical adverse events. Updated daily with expertly curated safety alerts, OFF-X covers more than 7,600 targets in all stages of drug R&D from emerging and first-in-class targets to targets for drugs that have reached the market.